FIG. 01 / THE CAPABILITY SYSTEM
CAPABILITY SYSTEM
THE OPERATING MODEL
KARAMATA brings specialized capabilities together within a delivery structure built for hematology and oncology. Each workstream has a defined owner. Decision paths are explicit. When work moves between functions, its context, responsibility, and open issues move with it.
Stop managing handoffs. Start driving outcomes.
FIG. 02 / THE STRUCTURAL DIFFERENCE
Attention and resources follow account size, while trials move through legacy delivery layers and one-size-fits-all processes.
We build senior-led, purpose-fit teams around the requirements of your protocol, creating clear accountability, direct visibility, and fewer layers between your team and the work.
We provide the precision and execution necessary to move it forward.
01 / OWNERSHIP
Named accountability for every agreed workstream.
02 / CONTINUITY
Context and open decisions move with the work.
03 / AUTHORITY
We prepare and coordinate. You decide, approve, and release.
FIG. 03 / REGULATORY DISCLOSURE
REGULATORY DISCLOSURE / HEMATOLOGY + ONCOLOGY
Keep your record current, complete, and compliant.
KARAMATA prepares and maintains ClinicalTrials.gov registration and results records within your organization’s PRS account, manages approved updates, and addresses QC comments. Your Responsible Party retains responsibility for release and certification.
DISCLOSURE WORKSTREAM
FIG. 04 / CLINICAL RESEARCH FINANCE
CLINICAL RESEARCH FINANCE / HEMATOLOGY + ONCOLOGY
Coverage analysis, billing grids, sponsor budgets, agreements, REC forms, CTMS build, and amendment support — carried through one accountable workstream.
FINANCE WORKSTREAM
RECRUITMENT WORKSTREAM
PATIENT RECRUITMENT & RETENTION
5to95™ helps sponsors and sites turn fragmented outreach, screening, enrollment, and follow-up into one coordinated path to participation — reaching beyond the patients already inside the trial system to the many who remain outside it.
START A CONVERSATION
Send the protocol, the synopsis, or a one-line description of where you are. You’ll get a scoped reply from the team that would run the study.
